Sanofi Genzyme is currently looking for sites to participate in the feasibility for an upcoming Sanofi Genzyme study to assess a diagnostic protocol for individuals with unexplained splenomegaly and thrombocytopenia. This study will determine the prevalence of Gaucher Disease and Acid Sphingomyelinase Deficiency (Niemann-Pick A and B) among individuals with splenomegaly and thrombocytopenia who meet additional inclusion and exclusion criteria. The study will also aim to determine the age of the patient at which Gaucher Disease and Acid Sphingomyelin Deficiency Disease is still undiagnosed and duration of disease specific signs and symptoms. Some relevant data will also be collected on personal history and prior medical records during the same visit. There will be no other therapeutic intervention involved in the study. If you are interested in learning more, please contact Ann Lucas, Medical Science Liaison, Rare Disease division at 980-266-3720, or ann.lucas@sanofi.com.
